NCT02244606Phase 2Completed

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2016-06Actual

Enrollment · participants27Actual

Source updated2024-06-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Mycoses; Candidiasis, Invasive; Candidemia

Treatments or interventions studied

SCY-078Drug
FluconazoleDrug
MicafunginDrug

Primary outcomes · main study measures

Read the study measures

measure: Safety and Tolerability, Assessed by Adverse Events, Clinical Laboratory Results, Physical Examination Findings, ECG Results, and Vital Sign Measurements; description: All Related TEAEs by SOC and PT, by Treatment, Safety; timeFrame: up to 10 weeks; measure: Dose of SCY-078 That Achieves the Target Exposure (AUC); description: Summary of PK Parameters on Day 1 by Treatment Arm, from non-compartmental analysis, PK; timeFrame: 0 to 24 hours post-dose

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history